Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publikationen 2006


  • Pogge von Strandmann E, Hansen H, Reiners K, Schnell R, Borchmann P, Merkert S, Draube A, Reiser M, Purr I, Hallek M, Engert A. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human myeloma in vitro and in vivo. Blood 107(5): 1955-1962 (2006) 
  • Engert A, Bredenfeld H. Döhner H. Ho A, Schmitz N, Berger D, Bacon P, Skacel T, Easton V, Diehl V. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: Results of a phase II study. Haematologica 91(4):546-549 (2006) 
  • Kober T, Trelle S, Engert A. Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals. J Natl Cancer Inst 98 (9):620-625 (2006)
  • Diehl V, Engert A. Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy? Nat Clin Pract Oncol 3(5): 227 (2006)
  • Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98 (10): 708-714 (2006)
  • Jensen M, Elter T, Engert A, Reiser M. Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab. Onkologie 29:90-92 (2006)
  • Engert A, Herbrecht R, Santoro A, Zinzani PL, Gorbatchevsky I. EXTEND PIX301: a phase III randomized trial of pxantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin’s lymphoma. Clin Lymphoma Myeloma 7: 152-154 (2006)
  • Strauss SJ, Morschhauser F, Rech J, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NKW, Goldenberg DM, Lister TA. A multicenter phase II trial of immunotherapy with humanized anti-CD22 antibody, Epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol 24 (24):3880-3886 (2006)
  • Bohlius J, Engert A. Antibiotics plus granulocyte colony-stimulating factor reduces febrile neutropenia in the first cycle of chemotherapy in people with small-cell lung cancer. Cancer Treat Rev 32(3)May:234-238 (2006)


  • Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J. Sekundärneoplasien nach erfolgreicher Primärtherapie des malignen Hodgkin-Lymphoms. Pathologe 27:47-52 (2006)
  • Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin – an updated overview. Nat Clin Pract Oncol 3 (3):152-164 (2006)
  • Kober T, Hülsewede H. Bohlius J, Engert A. Fourth Biannual Report of the Cochrane Haematological Malignancies Group. J Natl Cancer Inst 98 (8) (2006)
  • Eich HT, Haverkamp U, Engert A, Koch M, Skripnitchenko R, Brillant C, Sehlen S, Dühmke E, Diehl V, Müller RP. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin’s lymphoma – a comparison between extended-field and involved-field radiotherapy based on the data from the German Hodgkin Study Group (GHSG). American Journal of Oncology Review 5(3):175-177 (2006)
  • Sasse S, Diehl V, Engert A. Combined modality treatment for early-stage Hodgkin’s lymphoma: the GHSG experience. Haematologica reports 2(7):19-22 (2006)
  • Klimm B, Engert A, Diehl V. First-line treatment of Hodgkin’s lymphoma. Current Hematologic Malignancy Reports I:51-59 (2006)
  • Nogová L, Diehl V, Engert A for the GHSG. Nodular lymphocyte predominant Hodgkin’s lymphoma. Current Hematologic Malignancy Reports I:60-65 (2006) 
  • Klimm B, Engert A. New approaches for patients with advanced-stage and relapsed disease. Hematology (EHA Educ program) 3:166-171 (2006)
  • Naumann F, Weingart O, Kruse E, Schulz H, Bohlius J, Hülsewede H, Engert A. Fifth Biannual report of the Cochrane Haematologic Malignancies Group – Focus on Multiple Myeloma. J Natl Cancer Inst 98:2 (2006) 
  • Elter T, Hallek M, Engert A. Fludarabine in chronic lymphocytic leukaemia. Expert Opin Pharmacother 7(12): 1641-1651 (2006)
  • Nogova L, Rudiger T, Engert A. Biology, Cinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Hematology: 266-272 (2006)
  • Bredenfeld H. Engert A, Diehl V. 25 Jahre Deutsche Hodgkin Studiengruppe – ein Beitrag zur Versorgungsforschung. Der Onkologe 12:337-344 (2006) 
  • Chapuy B, Borchmann P, Engert A, Trümper L. Targeted-Therapie – neue Zielstrukturen und Substanzen in der Behandlung maligner Lymphome. Onkologe 12:651-58 (2006)
  • Krause SW, Schmitz S, Engert A. Leitlinie Morbus Hodgkin. Deutsche Gesellschaft für Hämatologie und Onkologie (DHGO). 2. Oktober (2006)